Immune globulin - Nihon Pharmaceutical

Drug Profile

Immune globulin - Nihon Pharmaceutical

Alternative Names: Immunoglobulin intravenous - Nihon Pharmaceutical; Kenketu Glovenin-I; Kenketu Glovenin-I-Nichiyaku; NPB-01

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nihon Pharmaceutical
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Agammaglobulinaemia; Chronic inflammatory demyelinating polyradiculoneuropathy; Pemphigus; Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • Phase III Bullous pemphigoid; Guillain-Barre syndrome; Motor neuron disease
  • Phase II Neuromyelitis optica

Most Recent Events

  • 01 Sep 2015 Nihon Pharmaceutical completes a phase III trial for Chronic inflammatory demyelinating polyradiculoneuropathy in Japan (NCT01824251)
  • 01 Jun 2015 Nihon Pharmaceutical completes a phase III trial for Motor neuron disease in Japan (NCT01827072)
  • 01 Jun 2014 Nihon Pharmaceutical completes a phase III trial in Stevens-Johnson syndrome and Toxic epidermal necrolysis in Japan (NCT01696500)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top